← Back to Clinical Trials
Recruiting NCT05447169

NCT05447169 Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05447169
Status Recruiting
Phase
Sponsor Sun Yat-sen University
Condition Nasopharyngeal Carcinoma
Study Type OBSERVATIONAL
Enrollment 11,625 participants
Start Date 2022-07-10
Primary Completion 2025-07-01

Eligibility & Interventions

Sex Male only
Min Age 30 Years
Max Age 62 Years
Study Type OBSERVATIONAL
Interventions
EBV antibodies testEBV DNA test

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 11,625 participants in total. It began in 2022-07-10 with a primary completion date of 2025-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.

Eligibility Criteria

Inclusion Criteria: * residents in Southern China * 30-62 years old * male * a first-degree relative of at least one nasopharyngeal carcinoma patient * no medical record of nasopharyngeal carcinoma * Eastern Cooperative Oncology Group score of 0-2 * be able to comprehend, sign, and date the written informed consent document to participate in the study Exclusion Criteria: * history of nasopharyngeal carcinoma * heavy cardiovascular, liver or kidney disease * on systemic steroid or immunosuppressant treatment or active autoimmune disease

Contact & Investigator

Central Contact

Ming-Yuan Chen, MD, PhD

✉ chmingy@mail.sysu.edu.cn

📞 86-20-8734-3361

Principal Investigator

Ming-Yuan Chen, MD, PhD

STUDY CHAIR

Sun Yat-sen University

Frequently Asked Questions

Who can join the NCT05447169 clinical trial?

This trial is open to male participants only, aged 30 Years or older, up to 62 Years, studying Nasopharyngeal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05447169 currently recruiting?

Yes, NCT05447169 is actively recruiting participants. Contact the research team at chmingy@mail.sysu.edu.cn for enrollment information.

Where is the NCT05447169 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT05447169 clinical trial?

NCT05447169 is sponsored by Sun Yat-sen University. The principal investigator is Ming-Yuan Chen, MD, PhD at Sun Yat-sen University. The trial plans to enroll 11,625 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology